vericel corp - VCEL
VCEL
Close Chg Chg %
35.69 0.61 1.71%
Closed Market
36.30
+0.61 (1.71%)
Volume: 558.32K
Last Updated:
Jun 5, 2026, 4:00 PM EDT
Company Overview: vericel corp - VCEL
VCEL Key Data
| Open $35.73 | Day Range 35.73 - 36.91 |
| 52 Week Range 28.95 - 45.97 | Market Cap $1.82B |
| Shares Outstanding 51.07M | Public Float 50.45M |
| Beta 1.12 | Rev. Per Employee N/A |
| P/E Ratio 87.26 | EPS $0.42 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 673.52K |
VCEL Performance
| 1 Week | 8.91% | ||
| 1 Month | 8.49% | ||
| 3 Months | 7.68% | ||
| 1 Year | -16.17% | ||
| 5 Years | -34.83% |
VCEL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About vericel corp - VCEL
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
VCEL At a Glance
Vericel Corp.
64 Sidney Street
Cambridge, Massachusetts 02139-4170
| Phone | 1-617-588-5555 | Revenue | 276.26M | |
| Industry | Pharmaceuticals: Major | Net Income | 16.52M | |
| Sector | Health Technology | 2025 Sales Growth | 16.455% | |
| Fiscal Year-end | 12 / 2026 | Employees | 398 | |
| View SEC Filings |
VCEL Valuation
| P/E Current | 87.262 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 113.704 |
| Price to Sales Ratio | 6.798 |
| Price to Book Ratio | 5.14 |
| Price to Cash Flow Ratio | 36.18 |
| Enterprise Value to EBITDA | 81.403 |
| Enterprise Value to Sales | 6.656 |
| Total Debt to Enterprise Value | 0.053 |
VCEL Efficiency
| Revenue/Employee | 694,118.09 |
| Income Per Employee | 41,502.513 |
| Receivables Turnover | 3.264 |
| Total Asset Turnover | 0.60 |
VCEL Liquidity
| Current Ratio | 5.034 |
| Quick Ratio | 4.677 |
| Cash Ratio | 2.798 |
VCEL Profitability
| Gross Margin | 74.423 |
| Operating Margin | 3.998 |
| Pretax Margin | 6.29 |
| Net Margin | 5.979 |
| Return on Assets | 3.588 |
| Return on Equity | 5.109 |
| Return on Total Capital | 3.647 |
| Return on Invested Capital | 4.023 |
VCEL Capital Structure
| Total Debt to Total Equity | 27.708 |
| Total Debt to Total Capital | 21.697 |
| Total Debt to Total Assets | 20.138 |
| Long-Term Debt to Equity | 23.737 |
| Long-Term Debt to Total Capital | 18.587 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Vericel Corp - VCEL
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 164.37M | 197.52M | 237.22M | 276.26M | |
Sales Growth
| +5.24% | +20.17% | +20.10% | +16.45% | |
Cost of Goods Sold (COGS) incl D&A
| 54.58M | 61.94M | 65.12M | 70.66M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 8.20M | 4.63M | 5.50M | 11.54M | |
Depreciation
| 8.20M | 4.03M | 4.90M | 10.94M | |
Amortization of Intangibles
| - | 600.00K | 600.00K | 600.00K | |
COGS Growth
| +8.81% | +13.49% | +5.13% | +8.51% | |
Gross Income
| 109.79M | 135.58M | 172.11M | 205.60M | |
Gross Income Growth
| +3.55% | +23.49% | +26.95% | +19.46% | |
Gross Profit Margin
| +66.80% | +68.64% | +72.55% | +74.42% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 126.85M | 142.04M | 167.59M | 194.56M | |
Research & Development
| 19.94M | 21.04M | 24.80M | 27.56M | |
Other SG&A
| 106.90M | 121.00M | 142.79M | 166.99M | |
SGA Growth
| +11.39% | +11.98% | +17.99% | +16.09% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (17.06M) | (6.46M) | 4.52M | 11.04M | |
Non Operating Income/Expense
| 1.44M | 4.70M | 6.61M | 6.96M | |
Non-Operating Interest Income
| 1.34M | 4.63M | 6.41M | 7.01M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 366.00K | 600.00K | 614.00K | 630.00K | |
Interest Expense Growth
| +9,050.00% | +63.93% | +2.33% | +2.61% | |
Gross Interest Expense
| 366.00K | 600.00K | 614.00K | 630.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (15.99M) | (2.37M) | 10.51M | 17.38M | |
Pretax Income Growth
| -110.87% | +85.19% | +543.83% | +65.34% | |
Pretax Margin
| -9.73% | -1.20% | +4.43% | +6.29% | |
Income Tax
| 721.00K | 814.00K | 148.00K | 859.00K | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (16.71M) | (3.18M) | 10.36M | 16.52M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (16.71M) | (3.18M) | 10.36M | 16.52M | |
Net Income Growth
| -123.65% | +80.96% | +425.64% | +59.41% | |
Net Margin Growth
| -10.17% | -1.61% | +4.37% | +5.98% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (16.71M) | (3.18M) | 10.36M | 16.52M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (16.71M) | (3.18M) | 10.36M | 16.52M | |
EPS (Basic)
| -0.3545 | -0.0669 | 0.2121 | 0.3281 | |
EPS (Basic) Growth
| -120.46% | +81.13% | +417.04% | +54.69% | |
Basic Shares Outstanding
| 47.13M | 47.59M | 48.85M | 50.34M | |
EPS (Diluted)
| -0.3545 | -0.0669 | 0.2005 | 0.3167 | |
EPS (Diluted) Growth
| -120.46% | +81.13% | +399.70% | +57.96% | |
Diluted Shares Outstanding
| 47.13M | 47.59M | 51.68M | 52.15M | |
EBITDA
| (8.86M) | (1.83M) | 10.02M | 22.59M | |
EBITDA Growth
| -1,796.15% | +79.31% | +647.11% | +125.36% | |
EBITDA Margin
| -5.39% | -0.93% | +4.23% | +8.18% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 55.429 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.023 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 0.472 | |
| Last Quarter’s Earnings | -0.12 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.32 | Next Fiscal Year Estimate | 0.877 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 8 |
| Mean Estimate | -0.02 | 0.08 | 0.47 | 0.88 |
| High Estimates | 0.03 | 0.12 | 0.64 | 1.13 |
| Low Estimate | -0.06 | 0.02 | 0.34 | 0.73 |
| Coefficient of Variance | -138.15 | 42.67 | 22.29 | 15.44 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Vericel Corp - VCEL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Vericel Corp - VCEL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 26, 2026 | Heidi M. Hagen Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 26, 2026 | Heidi M. Hagen Director | 31,850 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.41 per share | 1,032,258.50 |
| Mar 26, 2026 | Heidi M. Hagen Director | 46,850 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.76 per share | 129,306.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 7,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Michael Halpin Chief Operating Officer | 26,107 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Dominick C. Colangelo President and CEO; Director | 54,750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Dominick C. Colangelo President and CEO; Director | 36,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Dominick C. Colangelo President and CEO; Director | 312,446 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $38.09 per share | 11,901,068.14 |
| Feb 27, 2026 | Dominick C. Colangelo President and CEO; Director | 321,270 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Dominick C. Colangelo President and CEO; Director | 303,020 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 6,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan D. Siegal Principal Accounting Officer | 3,750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 10,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 13,650 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 75,556 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $38.25 per share | 2,890,017.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 76,192 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 74,692 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 73,192 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $38.09 per share | 2,787,883.28 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 74,527 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2026 | Jonathan Mark Hopper Chief Medical Officer | 71,377 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |